| Symbol | ANNX |
|---|---|
| Name | ANNEXON, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1400 SIERRA POINT PARKWAY, BLDG C,SUITE 200, BRISBANE, California, 94005, United States |
| Telephone | +1 650 822-5500 |
| Fax | — |
| — | |
| Website | https://www.annexonbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001528115 |
| Description | Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexons product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. Additional info from NASDAQ: |
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Read more📋 WIGGANS THOMAS G (Ex-Director) plans to sell 2K shares of Annexon, Inc. (at $6.32 each, total $13K) Filed: Jul 15, 2026 | ID: 005238
Read moreAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Read moreWaddill William D. 🟢 acquired 65.0K shares (1 derivative) of Annexon, Inc. (ANNX) at $4.70 Transaction Date: Jun 11, 2026 | Filing ID: 000001
Read moreSatter Muneer A 🟢 acquired 65.0K shares (1 derivative) of Annexon, Inc. (ANNX) at $4.70 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreJONES WILLIAM A JR 🟢 acquired 65.0K shares (1 derivative) of Annexon, Inc. (ANNX) at $4.70 Transaction Date: Jun 11, 2026 | Filing ID: 000001
Read moreCockroft Bettina M. 🟢 acquired 65.0K shares (1 derivative) of Annexon, Inc. (ANNX) at $4.70 Transaction Date: Jun 11, 2026 | Filing ID: 000001
Read moreChoi Jung 🟢 acquired 65.0K shares (1 derivative) of Annexon, Inc. (ANNX) at $4.70 Transaction Date: Jun 11, 2026 | Filing ID: 000001
Read moreCarson William H. 🟢 acquired 65.0K shares (1 derivative) of Annexon, Inc. (ANNX) at $4.70 Transaction Date: Jun 11, 2026 | Filing ID: 000005
Read moreYednock Ted 🟡 adjusted position in 0 shares (1 derivative) of Annexon, Inc. (ANNX) at $1.85 Transaction Date: Jun 11, 2026 | Filing ID: 000004
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07020819 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as A… | Phase3 | Guillain-Barre Syndrome | Recruiting | 2025-09-12 | 2028-06-30 | ClinicalTrials.gov |
| NCT06510816 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections … | Phase3 | Geographic Atrophy | Active_Not_Recruiting | 2024-07-30 | 2027-07-31 | ClinicalTrials.gov |
| NCT05780515 | A Study of ANX009 in Adult Participants With Lupus Nephritis | Phase1 | Lupus Nephritis | Completed | 2022-08-09 | 2023-10-31 | ClinicalTrials.gov |
| NCT05521269 | Dose Study of ANX1502 in Healthy Volunteers | Phase1 | Healthy | Completed | 2022-06-27 | 2024-11-19 | ClinicalTrials.gov |
| NCT05288881 | Single Ascending Dose Study of ANX105 | Phase1 | Healthy | Completed | 2022-02-28 | 2023-06-19 | ClinicalTrials.gov |
| NCT04691570 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Partic… | Phase2 | Warm Autoimmune Hemolytic Anemia (wAIHA) | Completed | 2021-11-10 | 2023-01-17 | ClinicalTrials.gov |
| NCT04656561 | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX… | Phase2 | Geographic Atrophy | Completed | 2021-02-26 | 2023-09-13 | ClinicalTrials.gov |
| NCT04569435 | Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2021-01-15 | 2024-04-23 | ClinicalTrials.gov |
| NCT04701164 | Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome | Phase3 | Guillain-Barre Syndrome | Completed | 2020-12-17 | 2024-04-20 | ClinicalTrials.gov |
| NCT04535752 | A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Voluntee… | Phase1 | Safety and Tolerability in Healthy Volunteers | Completed | 2020-10-30 | 2021-06-26 | ClinicalTrials.gov |
| NCT04514367 | An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntin… | Phase2 | Huntington Disease | Completed | 2020-08-17 | 2022-01-28 | ClinicalTrials.gov |
| NCT04035135 | A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (G… | Phase1 | Guillain-Barré Syndrome | Completed | 2020-01-29 | 2021-05-19 | ClinicalTrials.gov |
| NCT04188015 | Study of ANX007 in Participants With Primary Open-angle Glaucoma | Phase1 | Open Angle Glaucoma | Completed | 2018-07-25 | 2019-06-03 | ClinicalTrials.gov |
| NCT03488550 | Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma | Phase1 | Open-angle Glaucoma | Completed | 2018-03-23 | 2018-08-03 | ClinicalTrials.gov |
| NCT03010046 | Single Dose Study of ANX005 in Healthy Volunteers | Phase1 | Safety and Tolerability in Healthy Volunteers | Terminated | 2016-12-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT07424235 | Evaluating the Relationship Between Function and Structure in ARCHER II-like Po… | — | Age Related Macular Degeneration (AMD) | Completed | 2015-01-01 | 2024-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ANX005 | Other | Phase PHASE2 | Warm Autoimmune Hemolytic Anemia (wAIHA) | COMPLETED | NCT04691570 |
| Tanruprubart | Other | Phase PHASE3 | Guillain-Barre Syndrome | RECRUITING | NCT07020819 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Sham Procedure | Procedure | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 5.0mg ANX007 | Other | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 2.5mg ANX007 | Other | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| ANX007 | Other | Phase PHASE1 | Open-angle Glaucoma | COMPLETED | NCT03488550 |
| Placebos | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| IVIg | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| ANX005 | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| Intravenous immunoglobulin | Other | Phase PHASE1 | Guillain-Barré Syndrome | COMPLETED | NCT04035135 |
| ANX005 | Other | Phase PHASE1 | Guillain-Barré Syndrome | COMPLETED | NCT04035135 |
| Placebo | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | COMPLETED | NCT04535752 |
| ANX009 | Other | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | COMPLETED | NCT04535752 |
| ANX005 | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT04514367 |
| ANX005 | Other | Phase PHASE2 | Warm Autoimmune Hemolytic Anemia (wAIHA) | COMPLETED | NCT04691570 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288881 |
| ANX105 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288881 |
| Sham comparator | Other | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| ANX007 | Other | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| ANX009 | Other | Phase PHASE1 | Lupus Nephritis | COMPLETED | NCT05780515 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX1502 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX005 | Other | Phase PHASE2 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT04569435 |
| Placebo | Other | Phase PHASE3 | Guillain-Barre Syndrome | COMPLETED | NCT04701164 |
| ANX005 | Other | Phase PHASE3 | Guillain-Barre Syndrome | COMPLETED | NCT04701164 |
| Sham Administration | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Tanruprubart | Other | Phase PHASE3 | Guillain-Barre Syndrome | RECRUITING | NCT07020819 |
| Tanruprubart | DRUG | Phase PHASE3 | Guillain-Barre Syndrome | RECRUITING | NCT07020819 |
| Sham Administration | OTHER | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | DRUG | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| ANX1502 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX105 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT05288881 |
| Sham comparator | OTHER | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| Placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX009 | BIOLOGICAL | Phase PHASE1 | Lupus Nephritis | COMPLETED | NCT05780515 |
| Sham Procedure | OTHER | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 5.0mg ANX007 | BIOLOGICAL | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 2.5mg ANX007 | BIOLOGICAL | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| Intravenous immunoglobulin | DRUG | Phase PHASE1 | Guillain-Barré Syndrome | COMPLETED | NCT04035135 |
| ANX007 | DRUG | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| Placebos | DRUG | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| IVIg | DRUG | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| ANX005 | DRUG | Phase PHASE3 | Guillain-Barre Syndrome | COMPLETED | NCT04701164 |